PMC:7205724 / 9990-11458 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"314","span":{"begin":32,"end":40},"obj":"Species"},{"id":"315","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"318","span":{"begin":99,"end":107},"obj":"Species"},{"id":"319","span":{"begin":123,"end":131},"obj":"Disease"},{"id":"329","span":{"begin":346,"end":350},"obj":"Species"},{"id":"330","span":{"begin":408,"end":419},"obj":"Species"},{"id":"331","span":{"begin":458,"end":466},"obj":"Species"},{"id":"332","span":{"begin":544,"end":552},"obj":"Species"},{"id":"333","span":{"begin":558,"end":566},"obj":"Species"},{"id":"334","span":{"begin":334,"end":343},"obj":"Species"},{"id":"335","span":{"begin":571,"end":580},"obj":"Species"},{"id":"336","span":{"begin":366,"end":381},"obj":"Disease"},{"id":"337","span":{"begin":531,"end":540},"obj":"Disease"},{"id":"342","span":{"begin":663,"end":671},"obj":"Species"},{"id":"343","span":{"begin":706,"end":714},"obj":"Species"},{"id":"344","span":{"begin":687,"end":695},"obj":"Disease"},{"id":"345","span":{"begin":727,"end":735},"obj":"Disease"},{"id":"353","span":{"begin":1128,"end":1131},"obj":"Gene"},{"id":"354","span":{"begin":970,"end":978},"obj":"Species"},{"id":"355","span":{"begin":1054,"end":1062},"obj":"Species"},{"id":"356","span":{"begin":1193,"end":1201},"obj":"Species"},{"id":"357","span":{"begin":1211,"end":1220},"obj":"Species"},{"id":"358","span":{"begin":1283,"end":1292},"obj":"Species"},{"id":"359","span":{"begin":991,"end":999},"obj":"Disease"}],"attributes":[{"id":"A314","pred":"tao:has_database_id","subj":"314","obj":"Tax:9606"},{"id":"A315","pred":"tao:has_database_id","subj":"315","obj":"MESH:C000657245"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"Tax:9606"},{"id":"A319","pred":"tao:has_database_id","subj":"319","obj":"MESH:C000657245"},{"id":"A329","pred":"tao:has_database_id","subj":"329","obj":"Tax:114727"},{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"Tax:205488"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"Tax:1335626"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"Tax:9606"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"Tax:694009"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"Tax:11309"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"Tax:11309"},{"id":"A336","pred":"tao:has_database_id","subj":"336","obj":"MESH:D001102"},{"id":"A337","pred":"tao:has_database_id","subj":"337","obj":"MESH:D003643"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"Tax:9606"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"Tax:9606"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"MESH:C000657245"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:C000657245"},{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"Gene:1401"},{"id":"A354","pred":"tao:has_database_id","subj":"354","obj":"Tax:9606"},{"id":"A355","pred":"tao:has_database_id","subj":"355","obj":"Tax:9606"},{"id":"A356","pred":"tao:has_database_id","subj":"356","obj":"Tax:9606"},{"id":"A357","pred":"tao:has_database_id","subj":"357","obj":"Tax:2697049"},{"id":"A358","pred":"tao:has_database_id","subj":"358","obj":"Tax:2697049"},{"id":"A359","pred":"tao:has_database_id","subj":"359","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T70","span":{"begin":20,"end":26},"obj":"Body_part"},{"id":"T71","span":{"begin":87,"end":93},"obj":"Body_part"},{"id":"T72","span":{"begin":230,"end":236},"obj":"Body_part"},{"id":"T73","span":{"begin":604,"end":610},"obj":"Body_part"},{"id":"T74","span":{"begin":651,"end":657},"obj":"Body_part"},{"id":"T75","span":{"begin":819,"end":825},"obj":"Body_part"},{"id":"T76","span":{"begin":839,"end":847},"obj":"Body_part"},{"id":"T77","span":{"begin":1093,"end":1103},"obj":"Body_part"},{"id":"T78","span":{"begin":1171,"end":1177},"obj":"Body_part"},{"id":"T79","span":{"begin":1221,"end":1224},"obj":"Body_part"},{"id":"T80","span":{"begin":1269,"end":1275},"obj":"Body_part"},{"id":"T81","span":{"begin":1355,"end":1361},"obj":"Body_part"},{"id":"T82","span":{"begin":1461,"end":1467},"obj":"Body_part"}],"attributes":[{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T56","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"T57","span":{"begin":123,"end":131},"obj":"Disease"},{"id":"T58","span":{"begin":334,"end":350},"obj":"Disease"},{"id":"T59","span":{"begin":334,"end":343},"obj":"Disease"},{"id":"T60","span":{"begin":366,"end":381},"obj":"Disease"},{"id":"T61","span":{"begin":372,"end":381},"obj":"Disease"},{"id":"T62","span":{"begin":408,"end":413},"obj":"Disease"},{"id":"T63","span":{"begin":558,"end":566},"obj":"Disease"},{"id":"T64","span":{"begin":571,"end":580},"obj":"Disease"},{"id":"T65","span":{"begin":687,"end":695},"obj":"Disease"},{"id":"T66","span":{"begin":727,"end":735},"obj":"Disease"},{"id":"T67","span":{"begin":991,"end":999},"obj":"Disease"},{"id":"T68","span":{"begin":1211,"end":1215},"obj":"Disease"},{"id":"T69","span":{"begin":1283,"end":1287},"obj":"Disease"}],"attributes":[{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T103","span":{"begin":20,"end":26},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T104","span":{"begin":87,"end":93},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T105","span":{"begin":169,"end":170},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T106","span":{"begin":230,"end":236},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T107","span":{"begin":344,"end":345},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T108","span":{"begin":366,"end":371},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T109","span":{"begin":414,"end":419},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T110","span":{"begin":513,"end":514},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T111","span":{"begin":604,"end":610},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T112","span":{"begin":651,"end":657},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T113","span":{"begin":736,"end":737},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":751,"end":753},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T115","span":{"begin":764,"end":767},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T116","span":{"begin":819,"end":825},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T117","span":{"begin":966,"end":969},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T118","span":{"begin":1050,"end":1053},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T119","span":{"begin":1114,"end":1115},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T120","span":{"begin":1171,"end":1177},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T121","span":{"begin":1269,"end":1275},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T122","span":{"begin":1355,"end":1361},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T123","span":{"begin":1461,"end":1467},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T121","span":{"begin":895,"end":912},"obj":"Chemical"}],"attributes":[{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T6","span":{"begin":768,"end":780},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T7","span":{"begin":1093,"end":1109},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A6","pred":"meddra_id","subj":"T6","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062026"},{"id":"A7","pred":"meddra_id","subj":"T7","obj":"http://purl.bioontology.org/ontology/MEDDRA/10025251"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T46","span":{"begin":183,"end":190},"obj":"http://purl.obolibrary.org/obo/BFO_0000182"},{"id":"T47","span":{"begin":366,"end":371},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T48","span":{"begin":372,"end":381},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T49","span":{"begin":414,"end":419},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T82","span":{"begin":1221,"end":1224},"obj":"Chemical"}],"attributes":[{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_33697"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T73","span":{"begin":56,"end":64},"obj":"Species"},{"id":"T74","span":{"begin":123,"end":131},"obj":"Species"},{"id":"T75","span":{"begin":159,"end":168},"obj":"Species"},{"id":"T76","span":{"begin":346,"end":350},"obj":"Species"},{"id":"T77","span":{"begin":408,"end":419},"obj":"Species"},{"id":"T78","span":{"begin":458,"end":466},"obj":"Species"},{"id":"T79","span":{"begin":558,"end":566},"obj":"Species"},{"id":"T80","span":{"begin":687,"end":695},"obj":"Species"},{"id":"T81","span":{"begin":727,"end":735},"obj":"Species"},{"id":"T82","span":{"begin":991,"end":999},"obj":"Species"},{"id":"T83","span":{"begin":1211,"end":1220},"obj":"Species"},{"id":"T84","span":{"begin":1283,"end":1292},"obj":"Species"}],"attributes":[{"id":"A74","pred":"ncbi_taxonomy_id","subj":"T74","obj":"NCBItxid:2697049"},{"id":"A73","pred":"ncbi_taxonomy_id","subj":"T73","obj":"NCBItxid:2697049"},{"id":"A75","pred":"ncbi_taxonomy_id","subj":"T75","obj":"NCBItxid:2697049"},{"id":"A82","pred":"ncbi_taxonomy_id","subj":"T82","obj":"NCBItxid:2697049"},{"id":"A77","pred":"ncbi_taxonomy_id","subj":"T77","obj":"NCBItxid:1570291"},{"id":"A78","pred":"ncbi_taxonomy_id","subj":"T78","obj":"NCBItxid:1335626"},{"id":"A79","pred":"ncbi_taxonomy_id","subj":"T79","obj":"NCBItxid:694009"},{"id":"A81","pred":"ncbi_taxonomy_id","subj":"T81","obj":"NCBItxid:2697049"},{"id":"A83","pred":"ncbi_taxonomy_id","subj":"T83","obj":"NCBItxid:2697049"},{"id":"A76","pred":"ncbi_taxonomy_id","subj":"T76","obj":"NCBItxid:114727"},{"id":"A80","pred":"ncbi_taxonomy_id","subj":"T80","obj":"NCBItxid:2697049"},{"id":"A84","pred":"ncbi_taxonomy_id","subj":"T84","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T84","span":{"begin":0,"end":64},"obj":"Sentence"},{"id":"T85","span":{"begin":66,"end":86},"obj":"Sentence"},{"id":"T86","span":{"begin":87,"end":168},"obj":"Sentence"},{"id":"T87","span":{"begin":169,"end":284},"obj":"Sentence"},{"id":"T88","span":{"begin":285,"end":479},"obj":"Sentence"},{"id":"T89","span":{"begin":480,"end":616},"obj":"Sentence"},{"id":"T90","span":{"begin":618,"end":637},"obj":"Sentence"},{"id":"T91","span":{"begin":638,"end":735},"obj":"Sentence"},{"id":"T92","span":{"begin":736,"end":1000},"obj":"Sentence"},{"id":"T93","span":{"begin":1001,"end":1132},"obj":"Sentence"},{"id":"T94","span":{"begin":1133,"end":1302},"obj":"Sentence"},{"id":"T95","span":{"begin":1303,"end":1468},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"314","span":{"begin":32,"end":40},"obj":"Species"},{"id":"315","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"318","span":{"begin":99,"end":107},"obj":"Species"},{"id":"319","span":{"begin":123,"end":131},"obj":"Disease"},{"id":"334","span":{"begin":334,"end":343},"obj":"Species"},{"id":"329","span":{"begin":346,"end":350},"obj":"Species"},{"id":"336","span":{"begin":366,"end":381},"obj":"Disease"},{"id":"330","span":{"begin":408,"end":419},"obj":"Species"},{"id":"331","span":{"begin":458,"end":466},"obj":"Species"},{"id":"337","span":{"begin":531,"end":540},"obj":"Disease"},{"id":"332","span":{"begin":544,"end":552},"obj":"Species"},{"id":"333","span":{"begin":558,"end":566},"obj":"Species"},{"id":"335","span":{"begin":571,"end":580},"obj":"Species"},{"id":"342","span":{"begin":663,"end":671},"obj":"Species"},{"id":"344","span":{"begin":687,"end":695},"obj":"Disease"},{"id":"343","span":{"begin":706,"end":714},"obj":"Species"},{"id":"345","span":{"begin":727,"end":735},"obj":"Disease"},{"id":"354","span":{"begin":970,"end":978},"obj":"Species"},{"id":"359","span":{"begin":991,"end":999},"obj":"Disease"},{"id":"355","span":{"begin":1054,"end":1062},"obj":"Species"},{"id":"353","span":{"begin":1128,"end":1131},"obj":"Gene"},{"id":"356","span":{"begin":1193,"end":1201},"obj":"Species"},{"id":"357","span":{"begin":1211,"end":1220},"obj":"Species"},{"id":"358","span":{"begin":1283,"end":1292},"obj":"Species"}],"attributes":[{"id":"A335","pred":"pubann:denotes","subj":"335","obj":"Tax:11309"},{"id":"A331","pred":"pubann:denotes","subj":"331","obj":"Tax:1335626"},{"id":"A319","pred":"pubann:denotes","subj":"319","obj":"MESH:C000657245"},{"id":"A314","pred":"pubann:denotes","subj":"314","obj":"Tax:9606"},{"id":"A357","pred":"pubann:denotes","subj":"357","obj":"Tax:2697049"},{"id":"A330","pred":"pubann:denotes","subj":"330","obj":"Tax:205488"},{"id":"A333","pred":"pubann:denotes","subj":"333","obj":"Tax:694009"},{"id":"A343","pred":"pubann:denotes","subj":"343","obj":"Tax:9606"},{"id":"A337","pred":"pubann:denotes","subj":"337","obj":"MESH:D003643"},{"id":"A355","pred":"pubann:denotes","subj":"355","obj":"Tax:9606"},{"id":"A353","pred":"pubann:denotes","subj":"353","obj":"Gene:1401"},{"id":"A354","pred":"pubann:denotes","subj":"354","obj":"Tax:9606"},{"id":"A329","pred":"pubann:denotes","subj":"329","obj":"Tax:114727"},{"id":"A318","pred":"pubann:denotes","subj":"318","obj":"Tax:9606"},{"id":"A315","pred":"pubann:denotes","subj":"315","obj":"MESH:C000657245"},{"id":"A359","pred":"pubann:denotes","subj":"359","obj":"MESH:C000657245"},{"id":"A342","pred":"pubann:denotes","subj":"342","obj":"Tax:9606"},{"id":"A332","pred":"pubann:denotes","subj":"332","obj":"Tax:9606"},{"id":"A334","pred":"pubann:denotes","subj":"334","obj":"Tax:11309"},{"id":"A345","pred":"pubann:denotes","subj":"345","obj":"MESH:C000657245"},{"id":"A358","pred":"pubann:denotes","subj":"358","obj":"Tax:2697049"},{"id":"A336","pred":"pubann:denotes","subj":"336","obj":"MESH:D001102"},{"id":"A356","pred":"pubann:denotes","subj":"356","obj":"Tax:9606"},{"id":"A344","pred":"pubann:denotes","subj":"344","obj":"MESH:C000657245"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1222","span":{"begin":1128,"end":1131},"obj":"Protein"}],"attributes":[{"id":"A1222","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q5U0J2"},{"id":"A1223","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q07203"},{"id":"A1224","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/Q01687"},{"id":"A1225","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P97315"},{"id":"A1226","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P67967"},{"id":"A1227","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P67966"},{"id":"A1228","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P47875"},{"id":"A1229","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P32965"},{"id":"A1230","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P21291"},{"id":"A1231","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/P08462"},{"id":"A1232","pred":"uniprot_id","subj":"T1222","obj":"https://www.uniprot.org/uniprot/A8K268"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T34096","span":{"begin":0,"end":5},"obj":"CD"},{"id":"T81207","span":{"begin":7,"end":19},"obj":"JJ"},{"id":"T7654","span":{"begin":20,"end":26},"obj":"NN"},{"id":"T71050","span":{"begin":27,"end":31},"obj":"IN"},{"id":"T25890","span":{"begin":32,"end":40},"obj":"NNS"},{"id":"T44174","span":{"begin":41,"end":50},"obj":"VBN"},{"id":"T26910","span":{"begin":51,"end":55},"obj":"IN"},{"id":"T41378","span":{"begin":56,"end":64},"obj":"NN"},{"id":"T88463","span":{"begin":66,"end":73},"obj":"CD"},{"id":"T5371","span":{"begin":75,"end":85},"obj":"NN"},{"id":"T65084","span":{"begin":85,"end":86},"obj":"-COLON-"},{"id":"T11805","span":{"begin":87,"end":93},"obj":"NN"},{"id":"T86158","span":{"begin":94,"end":98},"obj":"IN"},{"id":"T7828","span":{"begin":99,"end":107},"obj":"NNS"},{"id":"T20215","span":{"begin":108,"end":117},"obj":"VBN"},{"id":"T19523","span":{"begin":118,"end":122},"obj":"IN"},{"id":"T35336","span":{"begin":123,"end":131},"obj":"NN"},{"id":"T99442","span":{"begin":132,"end":139},"obj":"VBP"},{"id":"T6188","span":{"begin":140,"end":150},"obj":"NNS"},{"id":"T80510","span":{"begin":151,"end":158},"obj":"IN"},{"id":"T57397","span":{"begin":159,"end":168},"obj":"NN"},{"id":"T57607","span":{"begin":169,"end":170},"obj":"DT"},{"id":"T47460","span":{"begin":171,"end":175},"obj":"NN"},{"id":"T44003","span":{"begin":176,"end":178},"obj":"IN"},{"id":"T20122","span":{"begin":179,"end":182},"obj":"DT"},{"id":"T89678","span":{"begin":183,"end":190},"obj":"NN"},{"id":"T33850","span":{"begin":191,"end":193},"obj":"IN"},{"id":"T21640","span":{"begin":194,"end":199},"obj":"JJ"},{"id":"T53029","span":{"begin":200,"end":209},"obj":"NNS"},{"id":"T73113","span":{"begin":210,"end":216},"obj":"VBZ"},{"id":"T71269","span":{"begin":217,"end":229},"obj":"JJ"},{"id":"T26722","span":{"begin":230,"end":236},"obj":"NN"},{"id":"T32817","span":{"begin":237,"end":239},"obj":"IN"},{"id":"T73367","span":{"begin":240,"end":243},"obj":"DT"},{"id":"T23573","span":{"begin":244,"end":248},"obj":"JJ"},{"id":"T80270","span":{"begin":249,"end":255},"obj":"NN"},{"id":"T50380","span":{"begin":256,"end":258},"obj":"TO"},{"id":"T14621","span":{"begin":259,"end":264},"obj":"VB"},{"id":"T15138","span":{"begin":265,"end":272},"obj":"JJ"},{"id":"T77639","span":{"begin":273,"end":283},"obj":"NNS"},{"id":"T94916","span":{"begin":285,"end":288},"obj":"DT"},{"id":"T85352","span":{"begin":289,"end":293},"obj":"RBS"},{"id":"T26901","span":{"begin":294,"end":300},"obj":"JJ"},{"id":"T70143","span":{"begin":301,"end":309},"obj":"NNS"},{"id":"T49434","span":{"begin":310,"end":317},"obj":"VBP"},{"id":"T54973","span":{"begin":318,"end":321},"obj":"DT"},{"id":"T39553","span":{"begin":322,"end":330},"obj":"NN"},{"id":"T56433","span":{"begin":331,"end":333},"obj":"IN"},{"id":"T99958","span":{"begin":334,"end":343},"obj":"NN"},{"id":"T27857","span":{"begin":344,"end":345},"obj":"NN"},{"id":"T52981","span":{"begin":346,"end":350},"obj":"NN"},{"id":"T85532","span":{"begin":351,"end":352},"obj":"-LRB-"},{"id":"T70555","span":{"begin":352,"end":361},"obj":"NN"},{"id":"T58026","span":{"begin":361,"end":362},"obj":"-RRB-"},{"id":"T49738","span":{"begin":363,"end":365},"obj":"IN"},{"id":"T7553","span":{"begin":366,"end":371},"obj":"NN"},{"id":"T41345","span":{"begin":372,"end":381},"obj":"NN"},{"id":"T46256","span":{"begin":382,"end":386},"obj":"CD"},{"id":"T28857","span":{"begin":386,"end":387},"obj":"-COMMA-"},{"id":"T13934","span":{"begin":388,"end":391},"obj":"DT"},{"id":"T20739","span":{"begin":392,"end":399},"obj":"NNP"},{"id":"T80018","span":{"begin":400,"end":407},"obj":"NNP"},{"id":"T70659","span":{"begin":408,"end":413},"obj":"NNP"},{"id":"T34284","span":{"begin":414,"end":419},"obj":"NN"},{"id":"T92495","span":{"begin":420,"end":428},"obj":"JJ"},{"id":"T36003","span":{"begin":429,"end":431},"obj":"IN"},{"id":"T12982","span":{"begin":432,"end":436},"obj":"CD"},{"id":"T49803","span":{"begin":436,"end":437},"obj":"-COMMA-"},{"id":"T90021","span":{"begin":438,"end":441},"obj":"CC"},{"id":"T16664","span":{"begin":442,"end":445},"obj":"DT"},{"id":"T58899","span":{"begin":446,"end":454},"obj":"NN"},{"id":"T11963","span":{"begin":455,"end":457},"obj":"IN"},{"id":"T71906","span":{"begin":458,"end":466},"obj":"NN"},{"id":"T74174","span":{"begin":467,"end":469},"obj":"IN"},{"id":"T70278","span":{"begin":470,"end":474},"obj":"CD"},{"id":"T44828","span":{"begin":475,"end":476},"obj":"-LRB-"},{"id":"T58846","span":{"begin":476,"end":477},"obj":"CD"},{"id":"T98769","span":{"begin":477,"end":478},"obj":"-RRB-"},{"id":"T44041","span":{"begin":480,"end":493},"obj":"NN"},{"id":"T92755","span":{"begin":494,"end":501},"obj":"NNS"},{"id":"T83388","span":{"begin":502,"end":506},"obj":"VBP"},{"id":"T75238","span":{"begin":507,"end":512},"obj":"VBN"},{"id":"T72067","span":{"begin":513,"end":514},"obj":"DT"},{"id":"T19254","span":{"begin":515,"end":522},"obj":"VBN"},{"id":"T86955","span":{"begin":523,"end":527},"obj":"NN"},{"id":"T79896","span":{"begin":528,"end":530},"obj":"IN"},{"id":"T13682","span":{"begin":531,"end":540},"obj":"NN"},{"id":"T55812","span":{"begin":541,"end":543},"obj":"IN"},{"id":"T18322","span":{"begin":544,"end":552},"obj":"NNS"},{"id":"T80297","span":{"begin":553,"end":557},"obj":"IN"},{"id":"T10571","span":{"begin":558,"end":566},"obj":"NN"},{"id":"T28781","span":{"begin":567,"end":570},"obj":"CC"},{"id":"T12582","span":{"begin":571,"end":580},"obj":"NN"},{"id":"T82834","span":{"begin":581,"end":590},"obj":"VBG"},{"id":"T84690","span":{"begin":591,"end":603},"obj":"JJ"},{"id":"T47738","span":{"begin":604,"end":610},"obj":"NN"},{"id":"T87902","span":{"begin":611,"end":612},"obj":"-LRB-"},{"id":"T15127","span":{"begin":612,"end":614},"obj":"CD"},{"id":"T21677","span":{"begin":614,"end":615},"obj":"-RRB-"},{"id":"T51845","span":{"begin":618,"end":625},"obj":"CD"},{"id":"T81264","span":{"begin":627,"end":636},"obj":"NNP"},{"id":"T56248","span":{"begin":636,"end":637},"obj":"-COLON-"},{"id":"T77485","span":{"begin":638,"end":650},"obj":"JJ"},{"id":"T80710","span":{"begin":651,"end":657},"obj":"NN"},{"id":"T37520","span":{"begin":658,"end":662},"obj":"IN"},{"id":"T57657","span":{"begin":663,"end":671},"obj":"NNS"},{"id":"T22774","span":{"begin":672,"end":681},"obj":"VBN"},{"id":"T85435","span":{"begin":682,"end":686},"obj":"IN"},{"id":"T50571","span":{"begin":687,"end":695},"obj":"NN"},{"id":"T48141","span":{"begin":696,"end":699},"obj":"MD"},{"id":"T93212","span":{"begin":700,"end":705},"obj":"VB"},{"id":"T48287","span":{"begin":706,"end":714},"obj":"NNS"},{"id":"T91679","span":{"begin":715,"end":719},"obj":"IN"},{"id":"T80666","span":{"begin":720,"end":726},"obj":"JJ"},{"id":"T17217","span":{"begin":727,"end":735},"obj":"NN"},{"id":"T94687","span":{"begin":736,"end":737},"obj":"DT"},{"id":"T22655","span":{"begin":738,"end":743},"obj":"NN"},{"id":"T19573","span":{"begin":744,"end":749},"obj":"NN"},{"id":"T23972","span":{"begin":750,"end":751},"obj":"-LRB-"},{"id":"T55337","span":{"begin":751,"end":753},"obj":"CD"},{"id":"T96728","span":{"begin":753,"end":754},"obj":"-RRB-"},{"id":"T92410","span":{"begin":755,"end":763},"obj":"RB"},{"id":"T26265","span":{"begin":764,"end":767},"obj":"VBZ"},{"id":"T35997","span":{"begin":768,"end":780},"obj":"VBN"},{"id":"T92380","span":{"begin":781,"end":784},"obj":"DT"},{"id":"T38590","span":{"begin":785,"end":791},"obj":"NN"},{"id":"T37156","span":{"begin":792,"end":795},"obj":"CC"},{"id":"T24661","span":{"begin":796,"end":802},"obj":"NN"},{"id":"T94632","span":{"begin":803,"end":805},"obj":"IN"},{"id":"T56352","span":{"begin":806,"end":818},"obj":"JJ"},{"id":"T65134","span":{"begin":819,"end":825},"obj":"NN"},{"id":"T64844","span":{"begin":826,"end":830},"obj":"WDT"},{"id":"T95987","span":{"begin":831,"end":838},"obj":"VBP"},{"id":"T86655","span":{"begin":839,"end":847},"obj":"NN"},{"id":"T45118","span":{"begin":848,"end":854},"obj":"NNS"},{"id":"T26321","span":{"begin":855,"end":861},"obj":"JJR"},{"id":"T17226","span":{"begin":862,"end":866},"obj":"IN"},{"id":"T2522","span":{"begin":867,"end":868},"obj":"CD"},{"id":"T48589","span":{"begin":868,"end":869},"obj":"-COLON-"},{"id":"T90182","span":{"begin":869,"end":872},"obj":"CD"},{"id":"T89317","span":{"begin":873,"end":881},"obj":"VBN"},{"id":"T28925","span":{"begin":882,"end":886},"obj":"IN"},{"id":"T68950","span":{"begin":887,"end":894},"obj":"JJ"},{"id":"T58621","span":{"begin":895,"end":905},"obj":"JJ"},{"id":"T22929","span":{"begin":906,"end":912},"obj":"NNS"},{"id":"T50644","span":{"begin":913,"end":916},"obj":"CC"},{"id":"T63224","span":{"begin":917,"end":925},"obj":"JJ"},{"id":"T22041","span":{"begin":926,"end":936},"obj":"JJ"},{"id":"T89053","span":{"begin":937,"end":941},"obj":"NN"},{"id":"T94835","span":{"begin":942,"end":944},"obj":"IN"},{"id":"T20257","span":{"begin":945,"end":953},"obj":"JJ"},{"id":"T49329","span":{"begin":954,"end":962},"obj":"NNS"},{"id":"T91601","span":{"begin":963,"end":965},"obj":"IN"},{"id":"T6238","span":{"begin":966,"end":969},"obj":"CD"},{"id":"T3048","span":{"begin":970,"end":978},"obj":"NNS"},{"id":"T18696","span":{"begin":979,"end":983},"obj":"IN"},{"id":"T93206","span":{"begin":984,"end":990},"obj":"JJ"},{"id":"T71443","span":{"begin":991,"end":999},"obj":"NN"},{"id":"T46997","span":{"begin":1001,"end":1004},"obj":"DT"},{"id":"T7672","span":{"begin":1005,"end":1010},"obj":"NN"},{"id":"T83098","span":{"begin":1011,"end":1017},"obj":"VBD"},{"id":"T5017","span":{"begin":1018,"end":1026},"obj":"JJ"},{"id":"T96870","span":{"begin":1027,"end":1038},"obj":"NN"},{"id":"T42442","span":{"begin":1039,"end":1041},"obj":"IN"},{"id":"T61149","span":{"begin":1042,"end":1045},"obj":"PDT"},{"id":"T89276","span":{"begin":1046,"end":1049},"obj":"DT"},{"id":"T53728","span":{"begin":1050,"end":1053},"obj":"CD"},{"id":"T50396","span":{"begin":1054,"end":1062},"obj":"NNS"},{"id":"T59179","span":{"begin":1063,"end":1074},"obj":"VBN"},{"id":"T83510","span":{"begin":1075,"end":1077},"obj":"IN"},{"id":"T2183","span":{"begin":1078,"end":1080},"obj":"DT"},{"id":"T4240","span":{"begin":1081,"end":1089},"obj":"NN"},{"id":"T18383","span":{"begin":1090,"end":1092},"obj":"IN"},{"id":"T99269","span":{"begin":1093,"end":1103},"obj":"NN"},{"id":"T12131","span":{"begin":1104,"end":1109},"obj":"NN"},{"id":"T36613","span":{"begin":1110,"end":1113},"obj":"CC"},{"id":"T91622","span":{"begin":1114,"end":1115},"obj":"DT"},{"id":"T39579","span":{"begin":1116,"end":1124},"obj":"NN"},{"id":"T72559","span":{"begin":1125,"end":1127},"obj":"IN"},{"id":"T31686","span":{"begin":1128,"end":1131},"obj":"NN"},{"id":"T20580","span":{"begin":1133,"end":1142},"obj":"VBG"},{"id":"T23341","span":{"begin":1143,"end":1154},"obj":"NN"},{"id":"T23846","span":{"begin":1155,"end":1157},"obj":"IN"},{"id":"T23496","span":{"begin":1158,"end":1170},"obj":"JJ"},{"id":"T68740","span":{"begin":1171,"end":1177},"obj":"NN"},{"id":"T74721","span":{"begin":1177,"end":1178},"obj":"-COMMA-"},{"id":"T3255","span":{"begin":1179,"end":1182},"obj":"PDT"},{"id":"T47829","span":{"begin":1183,"end":1186},"obj":"DT"},{"id":"T16466","span":{"begin":1187,"end":1192},"obj":"CD"},{"id":"T26913","span":{"begin":1193,"end":1201},"obj":"NNS"},{"id":"T47643","span":{"begin":1202,"end":1205},"obj":"WP"},{"id":"T10299","span":{"begin":1206,"end":1210},"obj":"VBD"},{"id":"T19318","span":{"begin":1211,"end":1220},"obj":"NN"},{"id":"T2642","span":{"begin":1221,"end":1224},"obj":"NN"},{"id":"T76428","span":{"begin":1225,"end":1233},"obj":"JJ"},{"id":"T59448","span":{"begin":1234,"end":1240},"obj":"IN"},{"id":"T49967","span":{"begin":1241,"end":1252},"obj":"NN"},{"id":"T2352","span":{"begin":1253,"end":1255},"obj":"IN"},{"id":"T3020","span":{"begin":1256,"end":1268},"obj":"JJ"},{"id":"T57517","span":{"begin":1269,"end":1275},"obj":"NN"},{"id":"T55829","span":{"begin":1276,"end":1282},"obj":"VBD"},{"id":"T39392","span":{"begin":1283,"end":1292},"obj":"NN"},{"id":"T26456","span":{"begin":1293,"end":1301},"obj":"JJ"},{"id":"T52249","span":{"begin":1303,"end":1308},"obj":"EX"},{"id":"T13795","span":{"begin":1309,"end":1313},"obj":"VBD"},{"id":"T15563","span":{"begin":1314,"end":1316},"obj":"DT"},{"id":"T53693","span":{"begin":1317,"end":1324},"obj":"NN"},{"id":"T35357","span":{"begin":1325,"end":1331},"obj":"NNS"},{"id":"T16756","span":{"begin":1332,"end":1341},"obj":"VBG"},{"id":"T53621","span":{"begin":1342,"end":1354},"obj":"JJ"},{"id":"T81904","span":{"begin":1355,"end":1361},"obj":"NN"},{"id":"T11852","span":{"begin":1362,"end":1367},"obj":"RB"},{"id":"T58859","span":{"begin":1368,"end":1370},"obj":"CC"},{"id":"T35171","span":{"begin":1371,"end":1379},"obj":"JJ"},{"id":"T39367","span":{"begin":1380,"end":1387},"obj":"NN"},{"id":"T20306","span":{"begin":1388,"end":1395},"obj":"IN"},{"id":"T63670","span":{"begin":1396,"end":1408},"obj":"JJ"},{"id":"T44856","span":{"begin":1409,"end":1416},"obj":"NN"},{"id":"T15733","span":{"begin":1417,"end":1419},"obj":"TO"},{"id":"T71428","span":{"begin":1420,"end":1428},"obj":"VB"},{"id":"T29390","span":{"begin":1429,"end":1432},"obj":"DT"},{"id":"T54708","span":{"begin":1433,"end":1437},"obj":"JJ"},{"id":"T64138","span":{"begin":1438,"end":1444},"obj":"NN"},{"id":"T21425","span":{"begin":1445,"end":1447},"obj":"IN"},{"id":"T75685","span":{"begin":1448,"end":1460},"obj":"JJ"},{"id":"T78861","span":{"begin":1461,"end":1467},"obj":"NN"}],"relations":[{"id":"R32394","pred":"arg1Of","subj":"T22929","obj":"T58621"},{"id":"R12539","pred":"arg1Of","subj":"T22929","obj":"T50644"},{"id":"R32883","pred":"arg2Of","subj":"T89053","obj":"T50644"},{"id":"R99734","pred":"arg1Of","subj":"T89053","obj":"T63224"},{"id":"R84751","pred":"arg1Of","subj":"T89053","obj":"T22041"},{"id":"R58957","pred":"arg1Of","subj":"T48589","obj":"T94835"},{"id":"R75573","pred":"arg2Of","subj":"T49329","obj":"T94835"},{"id":"R9700","pred":"arg1Of","subj":"T7654","obj":"T34096"},{"id":"R55934","pred":"arg1Of","subj":"T7654","obj":"T81207"},{"id":"R34567","pred":"arg1Of","subj":"T7654","obj":"T71050"},{"id":"R8614","pred":"arg2Of","subj":"T25890","obj":"T71050"},{"id":"R19161","pred":"arg2Of","subj":"T25890","obj":"T44174"},{"id":"R3402","pred":"arg1Of","subj":"T44174","obj":"T26910"},{"id":"R78843","pred":"arg2Of","subj":"T41378","obj":"T26910"},{"id":"R18397","pred":"arg1Of","subj":"T5371","obj":"T88463"},{"id":"R76601","pred":"arg1Of","subj":"T5371","obj":"T65084"},{"id":"R93481","pred":"arg1Of","subj":"T11805","obj":"T86158"},{"id":"R26398","pred":"arg2Of","subj":"T7828","obj":"T86158"},{"id":"R4590","pred":"arg2Of","subj":"T7828","obj":"T20215"},{"id":"R41132","pred":"arg1Of","subj":"T20215","obj":"T19523"},{"id":"R2213","pred":"arg2Of","subj":"T35336","obj":"T19523"},{"id":"R49394","pred":"arg1Of","subj":"T11805","obj":"T99442"},{"id":"R23547","pred":"arg2Of","subj":"T6188","obj":"T99442"},{"id":"R94604","pred":"arg1Of","subj":"T6188","obj":"T80510"},{"id":"R58884","pred":"arg2Of","subj":"T57397","obj":"T80510"},{"id":"R25631","pred":"arg1Of","subj":"T47460","obj":"T57607"},{"id":"R68452","pred":"arg1Of","subj":"T47460","obj":"T44003"},{"id":"R59048","pred":"arg2Of","subj":"T89678","obj":"T44003"},{"id":"R25939","pred":"arg1Of","subj":"T89678","obj":"T20122"},{"id":"R52150","pred":"arg1Of","subj":"T89678","obj":"T33850"},{"id":"R31752","pred":"arg2Of","subj":"T53029","obj":"T33850"},{"id":"R76424","pred":"arg1Of","subj":"T53029","obj":"T21640"},{"id":"R94096","pred":"arg1Of","subj":"T47460","obj":"T73113"},{"id":"R27652","pred":"arg2Of","subj":"T26722","obj":"T73113"},{"id":"R64711","pred":"arg1Of","subj":"T26722","obj":"T71269"},{"id":"R42164","pred":"arg1Of","subj":"T73113","obj":"T32817"},{"id":"R26531","pred":"arg2Of","subj":"T80270","obj":"T32817"},{"id":"R33232","pred":"arg1Of","subj":"T80270","obj":"T73367"},{"id":"R86011","pred":"arg1Of","subj":"T80270","obj":"T23573"},{"id":"R46142","pred":"arg1Of","subj":"T14621","obj":"T50380"},{"id":"R87244","pred":"modOf","subj":"T73113","obj":"T50380"},{"id":"R83234","pred":"arg1Of","subj":"T47460","obj":"T14621"},{"id":"R39441","pred":"arg2Of","subj":"T77639","obj":"T14621"},{"id":"R19535","pred":"arg1Of","subj":"T77639","obj":"T15138"},{"id":"R15380","pred":"arg1Of","subj":"T70143","obj":"T94916"},{"id":"R74510","pred":"arg1Of","subj":"T26901","obj":"T85352"},{"id":"R53215","pred":"arg1Of","subj":"T70143","obj":"T26901"},{"id":"R84591","pred":"arg1Of","subj":"T70143","obj":"T49434"},{"id":"R41319","pred":"arg2Of","subj":"T90021","obj":"T49434"},{"id":"R55406","pred":"arg1Of","subj":"T39553","obj":"T54973"},{"id":"R19973","pred":"arg1Of","subj":"T39553","obj":"T56433"},{"id":"R88239","pred":"arg2Of","subj":"T52981","obj":"T56433"},{"id":"R75498","pred":"arg1Of","subj":"T52981","obj":"T99958"},{"id":"R57082","pred":"arg1Of","subj":"T52981","obj":"T27857"},{"id":"R81932","pred":"arg1Of","subj":"T52981","obj":"T85532"},{"id":"R65037","pred":"arg2Of","subj":"T70555","obj":"T85532"},{"id":"R26598","pred":"arg3Of","subj":"T58026","obj":"T85532"},{"id":"R39309","pred":"arg1Of","subj":"T52981","obj":"T49738"},{"id":"R5982","pred":"arg2Of","subj":"T41345","obj":"T49738"},{"id":"R98776","pred":"arg1Of","subj":"T41345","obj":"T7553"},{"id":"R57317","pred":"arg1Of","subj":"T41345","obj":"T46256"},{"id":"R18532","pred":"arg1Of","subj":"T41345","obj":"T28857"},{"id":"R59147","pred":"arg2Of","subj":"T34284","obj":"T28857"},{"id":"R18564","pred":"arg1Of","subj":"T34284","obj":"T13934"},{"id":"R70515","pred":"arg1Of","subj":"T70659","obj":"T20739"},{"id":"R65296","pred":"arg1Of","subj":"T70659","obj":"T80018"},{"id":"R96279","pred":"arg1Of","subj":"T34284","obj":"T70659"},{"id":"R83132","pred":"arg1Of","subj":"T34284","obj":"T92495"},{"id":"R71366","pred":"arg1Of","subj":"T92495","obj":"T36003"},{"id":"R78893","pred":"arg2Of","subj":"T12982","obj":"T36003"},{"id":"R89583","pred":"arg1Of","subj":"T90021","obj":"T49803"},{"id":"R34230","pred":"arg1Of","subj":"T39553","obj":"T90021"},{"id":"R3169","pred":"arg2Of","subj":"T58899","obj":"T90021"},{"id":"R57304","pred":"arg1Of","subj":"T58899","obj":"T16664"},{"id":"R76318","pred":"arg1Of","subj":"T58899","obj":"T11963"},{"id":"R71138","pred":"arg2Of","subj":"T71906","obj":"T11963"},{"id":"R11171","pred":"arg1Of","subj":"T49434","obj":"T74174"},{"id":"R21352","pred":"arg2Of","subj":"T70278","obj":"T74174"},{"id":"R19361","pred":"arg1Of","subj":"T49434","obj":"T44828"},{"id":"R12803","pred":"arg2Of","subj":"T58846","obj":"T44828"},{"id":"R43811","pred":"arg3Of","subj":"T98769","obj":"T44828"},{"id":"R65283","pred":"arg1Of","subj":"T92755","obj":"T44041"},{"id":"R95414","pred":"arg1Of","subj":"T92755","obj":"T83388"},{"id":"R42612","pred":"arg2Of","subj":"T75238","obj":"T83388"},{"id":"R72806","pred":"arg1Of","subj":"T92755","obj":"T75238"},{"id":"R5113","pred":"arg2Of","subj":"T86955","obj":"T75238"},{"id":"R73986","pred":"arg1Of","subj":"T86955","obj":"T72067"},{"id":"R41187","pred":"arg2Of","subj":"T86955","obj":"T19254"},{"id":"R36473","pred":"arg1Of","subj":"T86955","obj":"T79896"},{"id":"R76627","pred":"arg2Of","subj":"T13682","obj":"T79896"},{"id":"R27621","pred":"arg1Of","subj":"T86955","obj":"T55812"},{"id":"R8881","pred":"arg2Of","subj":"T18322","obj":"T55812"},{"id":"R35442","pred":"arg1Of","subj":"T18322","obj":"T80297"},{"id":"R46656","pred":"arg2Of","subj":"T28781","obj":"T80297"},{"id":"R96095","pred":"arg1Of","subj":"T10571","obj":"T28781"},{"id":"R91436","pred":"arg2Of","subj":"T12582","obj":"T28781"},{"id":"R47598","pred":"arg1Of","subj":"T18322","obj":"T82834"},{"id":"R71140","pred":"arg2Of","subj":"T47738","obj":"T82834"},{"id":"R67016","pred":"arg1Of","subj":"T47738","obj":"T84690"},{"id":"R88979","pred":"arg1Of","subj":"T47738","obj":"T87902"},{"id":"R34245","pred":"arg2Of","subj":"T15127","obj":"T87902"},{"id":"R10750","pred":"arg3Of","subj":"T21677","obj":"T87902"},{"id":"R88677","pred":"arg1Of","subj":"T81264","obj":"T51845"},{"id":"R9567","pred":"arg1Of","subj":"T81264","obj":"T56248"},{"id":"R28137","pred":"arg1Of","subj":"T80710","obj":"T77485"},{"id":"R21152","pred":"arg1Of","subj":"T80710","obj":"T37520"},{"id":"R54555","pred":"arg2Of","subj":"T57657","obj":"T37520"},{"id":"R72924","pred":"arg2Of","subj":"T57657","obj":"T22774"},{"id":"R11993","pred":"arg1Of","subj":"T22774","obj":"T85435"},{"id":"R2179","pred":"arg2Of","subj":"T50571","obj":"T85435"},{"id":"R17226","pred":"arg1Of","subj":"T80710","obj":"T48141"},{"id":"R27403","pred":"arg2Of","subj":"T93212","obj":"T48141"},{"id":"R75667","pred":"arg1Of","subj":"T80710","obj":"T93212"},{"id":"R80215","pred":"arg2Of","subj":"T48287","obj":"T93212"},{"id":"R63671","pred":"arg1Of","subj":"T48287","obj":"T91679"},{"id":"R22614","pred":"arg2Of","subj":"T17217","obj":"T91679"},{"id":"R57108","pred":"arg1Of","subj":"T17217","obj":"T80666"},{"id":"R52082","pred":"arg1Of","subj":"T19573","obj":"T94687"},{"id":"R65194","pred":"arg1Of","subj":"T19573","obj":"T22655"},{"id":"R95106","pred":"arg1Of","subj":"T19573","obj":"T23972"},{"id":"R42168","pred":"arg2Of","subj":"T55337","obj":"T23972"},{"id":"R95339","pred":"arg3Of","subj":"T96728","obj":"T23972"},{"id":"R78448","pred":"arg1Of","subj":"T35997","obj":"T92410"},{"id":"R65706","pred":"arg1Of","subj":"T19573","obj":"T26265"},{"id":"R73941","pred":"arg2Of","subj":"T35997","obj":"T26265"},{"id":"R20951","pred":"arg1Of","subj":"T19573","obj":"T35997"},{"id":"R83087","pred":"arg2Of","subj":"T37156","obj":"T35997"},{"id":"R97536","pred":"arg1Of","subj":"T37156","obj":"T92380"},{"id":"R32731","pred":"arg1Of","subj":"T38590","obj":"T37156"},{"id":"R69272","pred":"arg2Of","subj":"T24661","obj":"T37156"},{"id":"R40627","pred":"arg1Of","subj":"T37156","obj":"T94632"},{"id":"R73729","pred":"arg2Of","subj":"T65134","obj":"T94632"},{"id":"R7895","pred":"arg1Of","subj":"T65134","obj":"T56352"},{"id":"R7377","pred":"arg1Of","subj":"T37156","obj":"T64844"},{"id":"R67249","pred":"arg1Of","subj":"T37156","obj":"T95987"},{"id":"R70225","pred":"arg2Of","subj":"T45118","obj":"T95987"},{"id":"R10830","pred":"arg1Of","subj":"T45118","obj":"T86655"},{"id":"R61261","pred":"arg1Of","subj":"T45118","obj":"T26321"},{"id":"R50969","pred":"arg1Of","subj":"T26321","obj":"T17226"},{"id":"R4008","pred":"arg2Of","subj":"T48589","obj":"T17226"},{"id":"R30054","pred":"arg1Of","subj":"T2522","obj":"T48589"},{"id":"R45762","pred":"arg2Of","subj":"T90182","obj":"T48589"},{"id":"R9970","pred":"arg2Of","subj":"T48589","obj":"T89317"},{"id":"R87348","pred":"arg1Of","subj":"T89317","obj":"T28925"},{"id":"R60332","pred":"arg2Of","subj":"T50644","obj":"T28925"},{"id":"R69387","pred":"arg1Of","subj":"T22929","obj":"T68950"},{"id":"R98484","pred":"arg1Of","subj":"T49329","obj":"T20257"},{"id":"R34116","pred":"arg1Of","subj":"T49329","obj":"T91601"},{"id":"R5522","pred":"arg2Of","subj":"T3048","obj":"T91601"},{"id":"R74118","pred":"arg1Of","subj":"T3048","obj":"T6238"},{"id":"R51409","pred":"arg1Of","subj":"T3048","obj":"T18696"},{"id":"R40479","pred":"arg2Of","subj":"T71443","obj":"T18696"},{"id":"R90019","pred":"arg1Of","subj":"T71443","obj":"T93206"},{"id":"R55615","pred":"arg1Of","subj":"T7672","obj":"T46997"},{"id":"R40867","pred":"arg1Of","subj":"T7672","obj":"T83098"},{"id":"R64658","pred":"arg2Of","subj":"T96870","obj":"T83098"},{"id":"R66056","pred":"arg1Of","subj":"T96870","obj":"T5017"},{"id":"R52864","pred":"arg1Of","subj":"T96870","obj":"T42442"},{"id":"R70060","pred":"arg2Of","subj":"T50396","obj":"T42442"},{"id":"R51479","pred":"arg1Of","subj":"T50396","obj":"T61149"},{"id":"R50628","pred":"arg1Of","subj":"T50396","obj":"T89276"},{"id":"R30895","pred":"arg1Of","subj":"T50396","obj":"T53728"},{"id":"R56320","pred":"arg1Of","subj":"T36613","obj":"T59179"},{"id":"R2541","pred":"arg2Of","subj":"T50396","obj":"T59179"},{"id":"R80186","pred":"arg2Of","subj":"T36613","obj":"T83510"},{"id":"R38806","pred":"arg1Of","subj":"T4240","obj":"T2183"},{"id":"R9880","pred":"arg1Of","subj":"T4240","obj":"T18383"},{"id":"R77420","pred":"arg2Of","subj":"T12131","obj":"T18383"},{"id":"R60391","pred":"arg1Of","subj":"T12131","obj":"T99269"},{"id":"R95922","pred":"arg1Of","subj":"T4240","obj":"T36613"},{"id":"R85485","pred":"arg2Of","subj":"T39579","obj":"T36613"},{"id":"R67798","pred":"arg1Of","subj":"T39579","obj":"T91622"},{"id":"R82541","pred":"arg1Of","subj":"T39579","obj":"T72559"},{"id":"R48725","pred":"arg2Of","subj":"T31686","obj":"T72559"},{"id":"R83808","pred":"arg1Of","subj":"T55829","obj":"T20580"},{"id":"R25087","pred":"arg2Of","subj":"T23341","obj":"T20580"},{"id":"R66336","pred":"arg1Of","subj":"T23341","obj":"T23846"},{"id":"R9016","pred":"arg2Of","subj":"T68740","obj":"T23846"},{"id":"R27767","pred":"arg1Of","subj":"T68740","obj":"T23496"},{"id":"R79010","pred":"arg1Of","subj":"T55829","obj":"T74721"},{"id":"R49789","pred":"arg1Of","subj":"T26913","obj":"T3255"},{"id":"R98083","pred":"arg1Of","subj":"T26913","obj":"T47829"},{"id":"R36266","pred":"arg1Of","subj":"T26913","obj":"T16466"},{"id":"R42101","pred":"arg1Of","subj":"T26913","obj":"T47643"},{"id":"R24725","pred":"arg1Of","subj":"T26913","obj":"T10299"},{"id":"R12375","pred":"arg2Of","subj":"T2642","obj":"T10299"},{"id":"R19448","pred":"arg1Of","subj":"T2642","obj":"T19318"},{"id":"R23710","pred":"arg1Of","subj":"T2642","obj":"T76428"},{"id":"R34529","pred":"arg1Of","subj":"T10299","obj":"T59448"},{"id":"R60141","pred":"arg2Of","subj":"T49967","obj":"T59448"},{"id":"R2931","pred":"arg1Of","subj":"T49967","obj":"T2352"},{"id":"R3822","pred":"arg2Of","subj":"T57517","obj":"T2352"},{"id":"R20207","pred":"arg1Of","subj":"T57517","obj":"T3020"},{"id":"R30096","pred":"arg1Of","subj":"T26913","obj":"T55829"},{"id":"R66579","pred":"arg2Of","subj":"T26456","obj":"T55829"},{"id":"R14919","pred":"arg1Of","subj":"T26456","obj":"T39392"},{"id":"R49718","pred":"arg1Of","subj":"T26913","obj":"T26456"},{"id":"R70070","pred":"arg1Of","subj":"T52249","obj":"T13795"},{"id":"R68506","pred":"arg2Of","subj":"T35357","obj":"T13795"},{"id":"R94657","pred":"arg1Of","subj":"T35357","obj":"T15563"},{"id":"R49835","pred":"arg1Of","subj":"T35357","obj":"T53693"},{"id":"R88768","pred":"arg1Of","subj":"T35357","obj":"T16756"},{"id":"R7103","pred":"arg2Of","subj":"T58859","obj":"T16756"},{"id":"R65241","pred":"arg1Of","subj":"T81904","obj":"T53621"},{"id":"R80896","pred":"arg1Of","subj":"T81904","obj":"T11852"},{"id":"R48507","pred":"arg1Of","subj":"T81904","obj":"T58859"},{"id":"R74990","pred":"arg2Of","subj":"T39367","obj":"T58859"},{"id":"R57531","pred":"arg1Of","subj":"T39367","obj":"T35171"},{"id":"R26123","pred":"arg1Of","subj":"T16756","obj":"T20306"},{"id":"R11811","pred":"arg2Of","subj":"T44856","obj":"T20306"},{"id":"R59105","pred":"arg1Of","subj":"T44856","obj":"T63670"},{"id":"R40530","pred":"arg1Of","subj":"T71428","obj":"T15733"},{"id":"R29016","pred":"modOf","subj":"T16756","obj":"T15733"},{"id":"R33735","pred":"arg2Of","subj":"T64138","obj":"T71428"},{"id":"R2474","pred":"arg1Of","subj":"T64138","obj":"T29390"},{"id":"R56840","pred":"arg1Of","subj":"T64138","obj":"T54708"},{"id":"R22469","pred":"arg1Of","subj":"T64138","obj":"T21425"},{"id":"R7749","pred":"arg2Of","subj":"T78861","obj":"T21425"},{"id":"R22133","pred":"arg1Of","subj":"T78861","obj":"T75685"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T70","span":{"begin":20,"end":26},"obj":"Body_part"},{"id":"T71","span":{"begin":87,"end":93},"obj":"Body_part"},{"id":"T72","span":{"begin":230,"end":236},"obj":"Body_part"},{"id":"T73","span":{"begin":604,"end":610},"obj":"Body_part"},{"id":"T74","span":{"begin":651,"end":657},"obj":"Body_part"},{"id":"T75","span":{"begin":819,"end":825},"obj":"Body_part"},{"id":"T76","span":{"begin":839,"end":847},"obj":"Body_part"},{"id":"T77","span":{"begin":1093,"end":1103},"obj":"Body_part"},{"id":"T78","span":{"begin":1171,"end":1177},"obj":"Body_part"},{"id":"T79","span":{"begin":1221,"end":1224},"obj":"Body_part"},{"id":"T80","span":{"begin":1269,"end":1275},"obj":"Body_part"},{"id":"T81","span":{"begin":1355,"end":1361},"obj":"Body_part"},{"id":"T82","span":{"begin":1461,"end":1467},"obj":"Body_part"}],"attributes":[{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A81","pred":"fma_id","subj":"T81","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T55","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"T56","span":{"begin":123,"end":131},"obj":"Disease"},{"id":"T57","span":{"begin":334,"end":350},"obj":"Disease"},{"id":"T58","span":{"begin":366,"end":381},"obj":"Disease"},{"id":"T59","span":{"begin":408,"end":413},"obj":"Disease"},{"id":"T60","span":{"begin":558,"end":566},"obj":"Disease"},{"id":"T61","span":{"begin":571,"end":580},"obj":"Disease"},{"id":"T62","span":{"begin":687,"end":695},"obj":"Disease"},{"id":"T63","span":{"begin":727,"end":735},"obj":"Disease"},{"id":"T64","span":{"begin":991,"end":999},"obj":"Disease"},{"id":"T65","span":{"begin":1211,"end":1220},"obj":"Disease"},{"id":"T66","span":{"begin":1283,"end":1292},"obj":"Disease"}],"attributes":[{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"LitCovid-sentences","denotations":[{"id":"T84","span":{"begin":0,"end":64},"obj":"Sentence"},{"id":"T85","span":{"begin":66,"end":86},"obj":"Sentence"},{"id":"T86","span":{"begin":87,"end":168},"obj":"Sentence"},{"id":"T87","span":{"begin":169,"end":284},"obj":"Sentence"},{"id":"T88","span":{"begin":285,"end":479},"obj":"Sentence"},{"id":"T89","span":{"begin":480,"end":616},"obj":"Sentence"},{"id":"T90","span":{"begin":618,"end":637},"obj":"Sentence"},{"id":"T91","span":{"begin":638,"end":735},"obj":"Sentence"},{"id":"T92","span":{"begin":736,"end":1000},"obj":"Sentence"},{"id":"T93","span":{"begin":1001,"end":1132},"obj":"Sentence"},{"id":"T94","span":{"begin":1133,"end":1302},"obj":"Sentence"},{"id":"T95","span":{"begin":1303,"end":1468},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}

{"project":"2_test","denotations":[{"id":"32413736-25030060-48112969","span":{"begin":612,"end":614},"obj":"25030060"},{"id":"T58999","span":{"begin":612,"end":614},"obj":"25030060"}],"text":"4.1.1 Convalescent plasma from patients recovered from COVID-19\n\n4.1.1.1 Hypothesis: Plasma from patients recovered from COVID-19 contain antibodies against 2019-nCoV\nA look at the history of viral outbreaks offers convalescent plasma as the only remedy to avoid further fatalities. The most recent examples include the pandemic of influenza A H1N1 (H1N1pdm09) in virus infection 2009, the Western African Ebola virus epidemic in 2014, and the outbreak of MERS-CoV in 2015 [9]. Meta-analysis studies have shown a reduced risk of mortality in patients with SARS-CoV and influenza receiving convalescent plasma [10].\n\n4.1.1.2 Rationale: Convalescent plasma from patients recovered from COVID-19 can treat patients with severe COVID-19\nA pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma."}